BR112021002090A8 - Derivado azabicíclico opticamente ativo - Google Patents

Derivado azabicíclico opticamente ativo

Info

Publication number
BR112021002090A8
BR112021002090A8 BR112021002090A BR112021002090A BR112021002090A8 BR 112021002090 A8 BR112021002090 A8 BR 112021002090A8 BR 112021002090 A BR112021002090 A BR 112021002090A BR 112021002090 A BR112021002090 A BR 112021002090A BR 112021002090 A8 BR112021002090 A8 BR 112021002090A8
Authority
BR
Brazil
Prior art keywords
optically active
azabicyclic derivative
derivative
active azabicyclic
mll
Prior art date
Application number
BR112021002090A
Other languages
English (en)
Other versions
BR112021002090A2 (pt
Inventor
Kamioka Seiji
Ban Hitoshi
Shimada Naoaki
Hirose Wataru
Arakawa Akihiko
Yamazaki Kazuto
Hira Kenjiro
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of BR112021002090A2 publication Critical patent/BR112021002090A2/pt
Publication of BR112021002090A8 publication Critical patent/BR112021002090A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

"DERIVADO AZABICÍCLICO OPTICAMENTE ATIVO". A presente invenção refere-se ao composto de fórmula (1a) em que p é 1 ou 2, R1 - R4 são átomo de hidrogênio ou similar, e a - d são 1 ou 2, ou um sal farmaceuticamente aceitável do mesmo, o qual tem um efeito antitumoral através da inibição da ligação entre uma proteína de fusão de MLL que é infundida com AF4, AF9, ou similar, que é um gene parceiro de fusão representativo causando leucemia MLL, e menin.
BR112021002090A 2018-08-27 2019-08-26 Derivado azabicíclico opticamente ativo BR112021002090A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018158315 2018-08-27
JP2018-158315 2018-08-27
PCT/JP2019/033234 WO2020045334A1 (ja) 2018-08-27 2019-08-26 光学活性なアザビシクロ環誘導体

Publications (2)

Publication Number Publication Date
BR112021002090A2 BR112021002090A2 (pt) 2021-05-04
BR112021002090A8 true BR112021002090A8 (pt) 2022-12-06

Family

ID=69644540

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021002090A BR112021002090A8 (pt) 2018-08-27 2019-08-26 Derivado azabicíclico opticamente ativo

Country Status (14)

Country Link
US (3) US11369605B2 (pt)
EP (1) EP3845533A4 (pt)
JP (3) JP6671574B1 (pt)
KR (1) KR20210049136A (pt)
CN (1) CN112585140B (pt)
AU (1) AU2019327006B2 (pt)
BR (1) BR112021002090A8 (pt)
CA (1) CA3107743A1 (pt)
EA (1) EA202190623A1 (pt)
MX (1) MX2021002424A (pt)
PH (1) PH12021550229A1 (pt)
SG (1) SG11202101085PA (pt)
TW (1) TWI815954B (pt)
WO (1) WO2020045334A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210198283A1 (en) * 2018-08-08 2021-07-01 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
CN112585140B (zh) * 2018-08-27 2023-07-04 住友制药株式会社 光学活性氮杂双环衍生物
WO2021060453A1 (ja) * 2019-09-27 2021-04-01 大日本住友製薬株式会社 架橋型光学活性２級アミン誘導体
JP7454520B2 (ja) 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
AR124379A1 (es) 2020-12-17 2023-03-22 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
JP2024518811A (ja) * 2021-12-03 2024-05-07 バイオノバ ファーマシューティカルズ（シャンハイ）リミティド カルボニル置換ジアザスピロ化合物及びその使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
AR039208A1 (es) 2002-04-03 2005-02-09 Syngenta Participations Ag Compuestos de fenil- y piridilalquinos, composicion herbicida que los contiene, procedimiento de preparacion de aquellos y procedimiento para combatir el crecimiento de plantas indeseadas
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
US9878987B2 (en) 2014-05-13 2018-01-30 Memorial Sloan Kettering Cancer Center HSP70 modulators and methods for making and using the same
US20190010167A1 (en) 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
SI3468966T1 (sl) * 2016-06-10 2021-03-31 Vitae Pharmaceuticals, Llc Zaviralci interakcije menin-MLL
CA3033239A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
TWI757340B (zh) 2016-09-16 2022-03-11 美商生命醫藥有限責任公司 梅嫩蛋白（ｍｅｎｉｎ）-ＭＬＬ相互作用之抑制劑
WO2018125992A1 (en) * 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
US10815241B2 (en) * 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN112585140B (zh) * 2018-08-27 2023-07-04 住友制药株式会社 光学活性氮杂双环衍生物

Also Published As

Publication number Publication date
MX2021002424A (es) 2021-04-28
AU2019327006B2 (en) 2024-02-15
JP2023134729A (ja) 2023-09-27
CN112585140B (zh) 2023-07-04
CA3107743A1 (en) 2020-03-05
EA202190623A1 (ru) 2021-05-21
SG11202101085PA (en) 2021-03-30
US20240148727A1 (en) 2024-05-09
US20210338668A1 (en) 2021-11-04
US11911381B2 (en) 2024-02-27
AU2019327006A1 (en) 2021-03-04
CN112585140A (zh) 2021-03-30
TWI815954B (zh) 2023-09-21
TW202024082A (zh) 2020-07-01
KR20210049136A (ko) 2021-05-04
JP6671574B1 (ja) 2020-03-25
US20220288072A1 (en) 2022-09-15
JP7317749B2 (ja) 2023-07-31
WO2020045334A1 (ja) 2020-03-05
EP3845533A4 (en) 2022-04-27
US11369605B2 (en) 2022-06-28
JP2020105191A (ja) 2020-07-09
JPWO2020045334A1 (ja) 2020-09-03
EP3845533A1 (en) 2021-07-07
PH12021550229A1 (en) 2021-10-11
BR112021002090A2 (pt) 2021-05-04

Similar Documents

Publication Publication Date Title
BR112021002090A8 (pt) Derivado azabicíclico opticamente ativo
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
TR201911032T4 (tr) Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
PH12020550432A1 (en) Compositions of phosphorylated tau peptides and uses thereof
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2019002864A (es) Mezcla aditiva.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
MD20230027A2 (ro) Amestecuri de pesticide cu conţinut de indazoli
NZ746906A (en) Oxaborole esters and uses thereof
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
MX2021003427A (es) Nuevos oxadiazoles.
PH12019502868A1 (en) Composition for injection
WO2018039077A8 (en) Therapeutic compounds
WO2018104729A8 (en) Ketamine derivatives
PH12021550329A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
MY197244A (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
AU2018270520A1 (en) Compounds for use as iron(III) MRI contrast agents

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)